Literature DB >> 3054127

Combining chemotherapy with biological response modifiers in treatment of cancer.

M S Mitchell1.   

Abstract

Combinations of chemotherapeutic agents with various biological response modifiers ("biomodulators") in the treatment of cancer are now being tested. Since most (though not all) chemotherapy is immunosuppressive, the schedules by which the chemotherapeutic agents and the biomodulators are combined are of critical importance. This review summarizes the effects of chemotherapy on immunity and suggests the most logical ways in which these categories of drugs might be combined with biomodulators. Specific examples are also provided of combination therapies that have proved useful or that are of significant potential utility. An understanding of the types of action and the mechanisms of action of specific chemotherapeutic agents and specific biomodulators may help to achieve additive effects (possibly synergism) with these combinations. At the very least, that understanding will avoid the hazard of one modality's negating the effects of the other.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3054127     DOI: 10.1093/jnci/80.18.1445

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

1.  Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors.

Authors:  Samdeep K Mouli; Patrick Tyler; Joseph L McDevitt; Aaron C Eifler; Yang Guo; Jodi Nicolai; Robert J Lewandowski; Weiguo Li; Daniel Procissi; Robert K Ryu; Y Andrew Wang; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  ACS Nano       Date:  2013-08-20       Impact factor: 15.881

Review 2.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

3.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

Authors:  E Kedar; Y Rutkowski; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

7.  Potentiation of cytotoxicity of mitomycin C by a polyacetylenic alcohol, panaxytriol.

Authors:  H Matsunaga; M Katano; T Saita; H Yamamoto; M Mori
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Effect of cisplatin upon expression of in vivo immune tumor resistance.

Authors:  E D Crum
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).

Authors:  L Tentori; C Leonetti; F Lozupone; E Bonmassar
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

10.  Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; D Bellgrau; J M Eule; J R Parra; Q Kong; K O Lillehei
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.